a-Methylacyl coenzyme A racemase is highly expressed in the intestinal-type adenocarcinoma and high-grade dysplasia lesions of the stomach.
To study a-Methylacyl coenzyme A racemase (AMACR) expression in gastric intestinal-type adenocarcinoma and its precursors, we performed an immunohistochemical assay (using an avidin-biotin-peroxidase complex method) on 106 paraffin-embedded gastric mucosal biopsy samples and 25 gastrectomy samples (37 negative for dysplasia; 30 indefinite for dysplasia; 22 low-grade dysplasia; 25 high-grade dysplasia; and 34 invasive intestinal adenocarcinoma). The results showed that AMACR staining was uniformly negative in the groups negative for dysplasia and indefinite for dysplasia. Only 1 of 22 (4.5%) low-grade dysplasia showed weak staining for AMACR. In the groups of high-grade dysplasia and invasive intestinal-type adenocarcinoma, however, 19 of 25 (76%) and 18 of 34 (52.9%) were positive for AMACR respectively. Expression of AMACR was not correlated with location, H. Pylori infection or intestinal metaplasia. These results suggested that AMACR may play a role in the intermediate stage of gastric carcinogenesis. The high level expression of AMACR in high-grade dysplasia and carcinoma suggests that it may be a useful biomarker in distinguishing high-grade dysplasia and carcinoma from low-grade dysplasia.